A handful of small caps, including Sensei and PDS, jumped on Asco abstract data, with much more news to come.
The first quarter of 2021 sets a new record, but the tide might be starting to turn.
The second quarter brings updates for Scholar Rock, Alnylam and Dicerna, among others.
Whether investor enthusiasm for drug stocks holds up this year is the burning question for IPO followers.
Myovant and Pfizer showed that deal-making was not taking a Christmas break, but for Celgene CVR holders the dream is almost over. And vaccine approvals gained pace.
In terms of venture financing, activity in 2017 outpaced that at the height of the biotech boom in 2015, with 68 biotechs attracted rounds of $50m or more.